Pressmeddelanden från AstraZeneca

Start Nyheter Forum Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Sonesitatug vedotin reduced the risk of death by 42% in 2nd- and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01 Igår 16:37

Tagrisso plus Orpathys reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on Tagrisso I förrgår 16:37

Imfinzi plus Imdelltra reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial I förrgår 16:31

Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer 22 okt 08:00

Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy 20 okt 15:11

Tezspire positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission 20 okt 06:06

AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes 19 okt 08:06

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, Imfinzi, Tagrisso and Orpathys 15 okt 12:00

AstraZeneca announces new strategic collaboration with insitro to use advanced AI systems to develop transformative therapeutics for difficult to treat cardiometabolic diseases 11 okt 23:01

Efzimfotase alfa showed numerical improvement in 6-Minute Walk Test achieving mean difference of 17.05 metres vs placebo in treatment-naïve adolescents, adults with HPP at week 25 in HICKORY Ph3 trial 06 okt 08:06

Alexion to showcase Phase III data in hypophosphatasia and hypoparathyroidism at ASBMR 2026 Annual Meeting 05 okt 18:11

AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts 05 okt 13:11

AstraZeneca completes equity investment in Summit Therapeutics 02 okt 08:31

AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types 29 sep 08:04

AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer 25 sep 08:01

Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer 24 sep 08:04

Alexion advances pioneering leadership in gMG care with data at 2026 AANEM Annual Meeting and MGFA Scientific Session 23 sep 08:01

Trixeo approved in the EU for the maintenance treatment of asthma 18 sep 15:08

Klygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG)18 sep 14:05

Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer 18 sep 08:04

Efzimfotase alfa granted Priority Review in the US as treatment for patients with hypophosphatasia aged 2 years and older 14 sep 08:06

Enhertu demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial 14 sep 08:01

Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer 14 sep 07:51

Tagrisso demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial 08 sep 15:02

Imfinzi+Imdelltra improved OS in small cell lung 08 sep 13:51

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials 07 sep 08:00

Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer 01 sep 08:31

Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer 01 sep 08:05

AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer 01 sep 08:02

Tagrisso plus Orpathys demonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer 27 aug 08:01

Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints 17 aug 08:35

Enhertu improved PFS in 1L HER2m lung cancer in DESTINY-Lung04 Phase III trial 17 aug 08:11

Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer 17 aug 08:05

Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer 31 jul 08:35

Datroway[ ]approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy 27 jul 08:10

Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant 27 jul 08:06

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers 27 jul 08:00

Resultat för AstraZeneca: Första halvåret samt andra kvartalet 2026 24 jul 13:09

Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer 24 jul 12:45

Trixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthma 23 jul 08:06

Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer 14 jul 08:09

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical 09 jul 08:07

Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy 29 jun 08:49

Efzimfotase alfa showed bone health improvements in treatment-naïve paediatric patients with hypophosphatasia: median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase 3 trial 29 jun 08:38

Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours 26 jun 13:15

Datroway[ ]recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy 15 jun 08:12

Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy 15 jun 08:07

Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer 08 jun 22:21

Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio 06 jun 10:35

Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo in adults with immunoglobulin A nephropathy at 34 weeks in I CAN Phase III trial 02 jun 14:06

Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 mutation in SERENA-6 trial 01 jun 14:11

Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial 29 maj 14:08

CARES Phase III clinical programme did not meet primary endpoint in overall AL amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa AL amyloidosis 29 maj 08:04

Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer 27 maj 08:04

US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data 22 maj 15:41

Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates 22 maj 14:17

Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours 22 maj 13:24

Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer 22 maj 08:06

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 18 maj 08:12

Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer 18 maj 08:07

Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension 14 maj 08:05

Imfinzi + EV improves EFS & OS in bladder cancer 12 maj 13:06

Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial 04 maj 08:18

Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer 04 maj 08:07

Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer 29 apr 08:00

Resultat för AstraZeneca: Första kvartalet 2026 28 apr 08:06

Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older 27 apr 08:06

Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus 23 apr 08:42

Change to AstraZeneca Board of Directors 21 apr 08:06

Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trial 20 apr 08:06

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD 10 apr 08:07

Alexion data at 2026 AAN Annual Meeting reflects industry-leading portfolio and commitment to enhancing care across rare diseases 02 apr 08:08

Imfinzi+Imjudo improves PFS in early liver cancer 31 mar 08:04

Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia 27 mar 08:10

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD 16 mar 08:07

Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers 10 mar 12:02

Notice of Annual General Meeting 09 mar 07:35

Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer 27 feb 08:03

Strensiq approved for restricted reimbursement in Sweden 25 feb 08:01

Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission 24 feb 12:02

Annual Financial Report 20 feb 08:39

Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in the 1st-line setting 13 feb 08:06

Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for Breztri in patients with uncontrolled asthma published in The Lancet Respiratory Medicine 10 feb 08:00

Resultat för AstraZeneca: Helåret samt fjärde kvartalet 2025 03 feb 08:34

Datroway granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy 03 feb 08:08

Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus 02 feb 08:09

Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers 02 feb 08:05

AstraZeneca begins trading on the New York Stock Exchange 30 jan 08:05

AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals 29 jan 10:57

AstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines 20 jan 08:05

AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange 08 jan 08:00

AstraZeneca appoints Joris Silon as Head of Investor Relations 06 jan 08:00

Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in systemic lupus erythematosus disease activity 22 dec 2025 08:30

Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer 22 dec 2025 08:00

Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer 16 dec 2025 08:10

Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus 16 dec 2025 08:07

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer 04 dec 2025 08:13

AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH 02 dec 2025 08:31

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension 26 nov 2025 08:01

Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers